Pancreatic Ductal Adenocarcinoma trials recruiting in Pennsylvania

All Pancreatic Ductal Adenocarcinoma trials nationally

Cities in Pennsylvania

Recruiting trials in Pennsylvania

• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07562152 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• Lead-212 PSV359 Therapy for Patients With Solid Tumors
  NCT06710756 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · Pennsylvania: Pittsburgh
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
  NCT07199764 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• Pancreatic Cancer Early Detection Consortium
  NCT04970056 · Phase: Not specified · Ages: 18 Years to 90 Years · Sex: All (male and female) · Pennsylvania: Philadelphia, Pittsburgh
• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
  NCT06218914 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia, Pittsburgh
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
  NCT05482893 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
  NCT06128551 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
  NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  NCT04851119 · Phase: Phase 1, Phase 2 · Ages: 12 Months to 30 Years · Sex: All (male and female) · Pennsylvania: Philadelphia, Pittsburgh